An unexpected discovery changed Alexandra’s life. “I had always envisioned having multiple kids,” she says.
But then she discovered that she had breast cancer, and her plans for how she would grow her family would have to change.
Alexandra was diagnosed with stage 3 breast cancer in July 2019 at an Atlanta-area breast care center. Once she learned of her diagnosis, her neighbor, an Emory University employee, recommended she meet with Jane Meisel, MD, a medical oncologist at Winship Cancer Institute of Emory University and associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
“When I got diagnosed,” says Alexandra, “I knew that I wanted to go see the best possible doctors. And as soon as I went to Winship Cancer Institute and met with Dr. Meisel, I knew that I was in the best possible hands. I knew she was going to put me on the best treatment path. She was going to sit there and hold my hand throughout the whole process. And that’s exactly what she did.”
After carefully examining Alexandra’s biopsy specimen, Dr. Meisel determined that her cancer had two different targets, kind of like bullseyes for treatment. One target is an elevated level of a protein called HER2, also known as “HER2-positive,” and the other is an elevated level of the estrogen receptor, which is called “ER-positive.” About two thirds of HER2-positive breast cancers are also ER-positive, and as Dr. Meisel explained, this could be used to her advantage in developing a targeted, personalized plan for therapy.
Alexandra was treated with combination chemotherapy and anti-HER2 therapy and then underwent a double mastectomy. Again, the surgical specimen underwent a careful review. The cancer that was removed from her breast and lymph nodes under her arm pits had even higher levels of estrogen receptors than it had before chemotherapy, so Dr. Meisel explained that aggressive anti-estrogen therapy would also be an important part of her care.
Alexandra says that another reason she came to Winship was that she knew if she needed a trial drug or more in-depth research, “Emory was the place that I would want to be.”
In fact, after a year of treatment, Alexandra chose to add a drug that had been very recently approved to further reduce the risk of recurrence.
“Making it through chemo and having great doctors, great bedside manner, and being offered the chance to take that new drug just proved that I was in the right place,” says Alexandra.